Marksans Pharma Ltd.
•₹ 321.30.14%
2026-08-21
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 22.0%
- Company has consistently been profitable over the last 5 years
- Latest quarter profit grew 173.9% YoY, showing strong momentum
- Company has delivered good sales growth of 16.5% CAGR over last 5 years
CONS
- Though reporting repeated profits, the company pays out little dividend (9.8%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1898.00 | 37.65 | 455393.78 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8525.00 | 77.37 | 226311.96 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 5013.00 | 87.43 | 190678.41 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1416.00 | 33.94 | 114392.01 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1105.00 | 24.42 | 110224.17 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2220.00 | 18.36 | 101506.15 | 0.81 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | MANKIND | 2391.00 | 48.34 | 98747.34 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 8. | DRREDDY | 1171.00 | 30.33 | 97740.54 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 9. | LAURUSLABS | 1807.00 | 89.30 | 97634.42 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1615.15 | 25.03 | 92932.16 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 414.30 | 136.32 | 67518.23 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | MARKSANS | 327.45 | 28.72 | 14838.85 | 0.27 | 159.41 | 173.89 | 840.80 | 35.61 | 21.10 | 25.34 |
Detailed Comparison with:
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 | 754 | 856 | 841 | |
| 398 | 417 | 453 | 450 | 462 | 495 | 551 | 582 | 520 | 576 | 594 | 661 | 660 | |
| Operating Profit | — | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Income | 10 | 19 | 5 | 17 | 15 | -0 | 36 | 15 | 6 | 22 | 20 | 35 | 25 |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 |
| Depreciation | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 | 24 | 24 | 25 |
| 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 | 151 | 200 | 207 | |
| Tax % | 27.25% | 26.30% | 26.35% | 22.57% | 25.79% | 21.54% | 26.66% | 21.85% | 24.02% | 25.65% | 24.52% | 25.49% | 22.83% |
| Net Profit | 0 | 0 | 0 | 0 | 89 | 98 | 105 | 91 | 58 | 99 | 114 | 149 | 159 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 3 | 0 | |
| Equity Capital | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Equity Capital | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Jun 2023
- 500
- 398
- Operating Profit
- —
- OPM %
- —
- Other Income
- 10
- Interest
- 2
- Depreciation
- 14
- 97
- Tax %
- 27.25%
- Net Profit
- 0
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2023
- 531
- 417
- Operating Profit
- —
- OPM %
- —
- Other Income
- 19
- Interest
- 2
- Depreciation
- 18
- 114
- Tax %
- 26.30%
- Net Profit
- 0
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2023
- 586
- 453
- Operating Profit
- —
- OPM %
- —
- Other Income
- 5
- Interest
- 3
- Depreciation
- 22
- 113
- Tax %
- 26.35%
- Net Profit
- 0
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2024
- 560
- 450
- Operating Profit
- —
- OPM %
- —
- Other Income
- 17
- Interest
- 5
- Depreciation
- 21
- 100
- Tax %
- 22.57%
- Net Profit
- 0
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2024
- 591
- 462
- Operating Profit
- —
- OPM %
- —
- Other Income
- 15
- Interest
- 3
- Depreciation
- 20
- 120
- Tax %
- 25.79%
- Net Profit
- 89
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2024
- 642
- 495
- Operating Profit
- —
- OPM %
- —
- Other Income
- -0
- Interest
- 3
- Depreciation
- 20
- 125
- Tax %
- 21.54%
- Net Profit
- 98
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2024
- 682
- 551
- Operating Profit
- —
- OPM %
- —
- Other Income
- 36
- Interest
- 3
- Depreciation
- 21
- 143
- Tax %
- 26.66%
- Net Profit
- 105
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2025
- 708
- 582
- Operating Profit
- —
- OPM %
- —
- Other Income
- 15
- Interest
- 3
- Depreciation
- 23
- 116
- Tax %
- 21.85%
- Net Profit
- 91
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2025
- 620
- 520
- Operating Profit
- —
- OPM %
- —
- Other Income
- 6
- Interest
- 6
- Depreciation
- 23
- 77
- Tax %
- 24.02%
- Net Profit
- 58
- 1
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2025
- 720
- 576
- Operating Profit
- —
- OPM %
- —
- Other Income
- 22
- Interest
- 6
- Depreciation
- 27
- 133
- Tax %
- 25.65%
- Net Profit
- 99
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2025
- 754
- 594
- Operating Profit
- —
- OPM %
- —
- Other Income
- 20
- Interest
- 6
- Depreciation
- 24
- 151
- Tax %
- 24.52%
- Net Profit
- 114
- 2
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2026
- 856
- 661
- Operating Profit
- —
- OPM %
- —
- Other Income
- 35
- Interest
- 6
- Depreciation
- 24
- 200
- Tax %
- 25.49%
- Net Profit
- 149
- 3
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2026
- 841
- 660
- Operating Profit
- —
- OPM %
- —
- Other Income
- 25
- Interest
- 7
- Depreciation
- 25
- 207
- Tax %
- 22.83%
- Net Profit
- 159
- 0
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 45
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 | 3,172 | |
| 734 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,090 | 2,350 | 2,490 | |
| Operating Profit | 52 | 87 | 137 | 193 | 346 | 301 | 399 | 509 | 599 | 683 | — |
| OPM % | 7 | 10 | 14 | 17 | 25 | 20 | 22 | 23 | 23 | 23 | — |
| Other Income | 19 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 66 | 83 | 102 |
| Interest | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 24 | 25 |
| Depreciation | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 99 | 100 |
| 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 561 | 691 | |
| Tax % | 24 | 28 | 23 | 23 | 21 | 25 | 21 | 26 | 24 | 25 | 25 |
| Net Profit | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 | 521 |
| EPS | 0 | 1 | 2 | 3 | 6 | 5 | 6 | 7 | 8 | 9 | — |
| Dividend Payout % | 23 | 6 | 3 | 3 | 4 | 6 | 9 | 9 | 10 | 10 | — |
| Minority Interest | -2 | -3 | -4 | -4 | -3 | -2 | 1 | -1 | -2 | -2 | -1 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 0 | 1 | 2 | 3 | 6 | 5 | 6 | 7 | 8 | 9 | — |
| Minority Interest | -2 | -3 | -4 | -4 | -3 | -2 | 1 | -1 | -2 | -2 | -1 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 0 | 1 | 2 | 3 | 6 | 5 | 6 | 7 | 8 | 9 | — |
Mar 2017
- 767
- 734
- Operating Profit
- 52
- OPM %
- 7
- Other Income
- 19
- Interest
- 7
- Depreciation
- 30
- 15
- Tax %
- 24
- Net Profit
- 11
- EPS
- 0
- Dividend Payout %
- 23
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 0
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 0
Mar 2018
- 913
- 834
- Operating Profit
- 87
- OPM %
- 10
- Other Income
- 8
- Interest
- 10
- Depreciation
- 27
- 50
- Tax %
- 28
- Net Profit
- 36
- EPS
- 1
- Dividend Payout %
- 6
- Minority Interest
- -3
- Share of Associates
- 0
- Adjusted EPS
- 1
- Minority Interest
- -3
- Share of Associates
- 0
- Adjusted EPS
- 1
Mar 2019
- 1,000
- 868
- Operating Profit
- 137
- OPM %
- 14
- Other Income
- 5
- Interest
- 10
- Depreciation
- 23
- 104
- Tax %
- 23
- Net Profit
- 80
- EPS
- 2
- Dividend Payout %
- 3
- Minority Interest
- -4
- Share of Associates
- 0
- Adjusted EPS
- 2
- Minority Interest
- -4
- Share of Associates
- 0
- Adjusted EPS
- 2
Mar 2020
- 1,134
- 942
- Operating Profit
- 193
- OPM %
- 17
- Other Income
- 0
- Interest
- 9
- Depreciation
- 27
- 157
- Tax %
- 23
- Net Profit
- 121
- EPS
- 3
- Dividend Payout %
- 3
- Minority Interest
- -4
- Share of Associates
- 0
- Adjusted EPS
- 3
- Minority Interest
- -4
- Share of Associates
- 0
- Adjusted EPS
- 3
Mar 2021
- 1,376
- 1,037
- Operating Profit
- 346
- OPM %
- 25
- Other Income
- 7
- Interest
- 8
- Depreciation
- 36
- 302
- Tax %
- 21
- Net Profit
- 239
- EPS
- 6
- Dividend Payout %
- 4
- Minority Interest
- -3
- Share of Associates
- 0
- Adjusted EPS
- 6
- Minority Interest
- -3
- Share of Associates
- 0
- Adjusted EPS
- 6
Mar 2022
- 1,491
- 1,232
- Operating Profit
- 301
- OPM %
- 20
- Other Income
- 42
- Interest
- 8
- Depreciation
- 45
- 248
- Tax %
- 25
- Net Profit
- 187
- EPS
- 5
- Dividend Payout %
- 6
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 5
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 5
Mar 2023
- 1,852
- 1,513
- Operating Profit
- 399
- OPM %
- 22
- Other Income
- 59
- Interest
- 9
- Depreciation
- 52
- 338
- Tax %
- 21
- Net Profit
- 265
- EPS
- 6
- Dividend Payout %
- 9
- Minority Interest
- 1
- Share of Associates
- 0
- Adjusted EPS
- 6
- Minority Interest
- 1
- Share of Associates
- 0
- Adjusted EPS
- 6
Mar 2024
- 2,177
- 1,719
- Operating Profit
- 509
- OPM %
- 23
- Other Income
- 50
- Interest
- 11
- Depreciation
- 74
- 424
- Tax %
- 26
- Net Profit
- 315
- EPS
- 7
- Dividend Payout %
- 9
- Minority Interest
- -1
- Share of Associates
- 0
- Adjusted EPS
- 7
- Minority Interest
- -1
- Share of Associates
- 0
- Adjusted EPS
- 7
Mar 2025
- 2,623
- 2,090
- Operating Profit
- 599
- OPM %
- 23
- Other Income
- 66
- Interest
- 12
- Depreciation
- 83
- 504
- Tax %
- 24
- Net Profit
- 383
- EPS
- 8
- Dividend Payout %
- 10
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 8
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 8
Mar 2026
- 2,951
- 2,350
- Operating Profit
- 683
- OPM %
- 23
- Other Income
- 83
- Interest
- 24
- Depreciation
- 99
- 561
- Tax %
- 25
- Net Profit
- 420
- EPS
- 9
- Dividend Payout %
- 10
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 9
- Minority Interest
- -2
- Share of Associates
- 0
- Adjusted EPS
- 9
TTM
- 3,172
- 2,490
- Operating Profit
- —
- OPM %
- —
- Other Income
- 102
- Interest
- 25
- Depreciation
- 100
- 691
- Tax %
- 25
- Net Profit
- 521
- EPS
- —
- Dividend Payout %
- —
- Minority Interest
- -1
- Share of Associates
- 0
- Adjusted EPS
- —
- Minority Interest
- -1
- Share of Associates
- 0
- Adjusted EPS
- —
COMPOUNDED SALES GROWTH
- 10 Years:
- 13%
- 5 Years:
- 16%
- 3 Years:
- 17%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 18%
- 5 Years:
- 12%
- 3 Years:
- 16%
STOCK PRICE CAGR
- 10 Years:
- 23%
- 5 Years:
- 36%
- 3 Years:
- 43%
- 1 Year:
- 77%
RETURN ON EQUITY
- 10 Years:
- 16%
- 5 Years:
- 17%
- 3 Years:
- 16%
- Last Year:
- 15%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - | - | - | - |
| Equity Capital | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| 393 | 430 | 502 | 595 | 846 | 1,068 | 1,700 | 2,020 | 2,422 | 2,975 | |
| 110 | 117 | 100 | 19 | 19 | 41 | 42 | 29 | 23 | 30 | |
| Trade Payables | 162 | 78 | 106 | 110 | 169 | 200 | 231 | 268 | 306 | 337 |
| 47 | 65 | 54 | 137 | 154 | 310 | 173 | 319 | 444 | 462 | |
| Total Liabilities | 752 | 731 | 802 | 902 | 1,228 | 1,660 | 2,190 | 2,681 | 3,240 | 3,848 |
| ASSETS | - | - | - | - | - | - | - | - | - | - |
| 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,044 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 6 | 1 | 7 | 5 | 9 | 15 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 0 | |
| 190 | 218 | 293 | 242 | 404 | 424 | 485 | 618 | 846 | 972 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 453 | 540 | 645 | |
| Cash & Bank | 25 | 40 | 34 | 94 | 212 | 349 | 715 | 674 | 704 | 990 |
| 269 | 193 | 206 | 264 | 296 | 457 | 497 | 128 | 158 | 183 | |
| Total Assets | 752 | 731 | 802 | 902 | 1,228 | 1,660 | 2,190 | 2,681 | 3,240 | 3,848 |
| Total Debt | 110 | 118 | 100 | 19 | 19 | 41 | 42 | 29 | 23 | 30 |
| Net Working Capital | 188 | 216 | 299 | 365 | 604 | 845 | 1,334 | 1,473 | 1,727 | 2,196 |
| Contingent Liabilities | 9 | 11 | 30 | 48 | 20 | 1 | 1 | 0 | 0 | 0 |
| Book Value per Share | 10.59 | 11.50 | 13.25 | 15.54 | 21.66 | 27.10 | 38.51 | 45.57 | 54.44 | 66.64 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total Debt | 110 | 118 | 100 | 19 | 19 | 41 | 42 | 29 | 23 | 30 |
| Net Working Capital | 188 | 216 | 299 | 365 | 604 | 845 | 1,334 | 1,473 | 1,727 | 2,196 |
| Contingent Liabilities | 9 | 11 | 30 | 48 | 20 | 1 | 1 | 0 | 0 | 0 |
| Book Value per Share | 10.59 | 11.50 | 13.25 | 15.54 | 21.66 | 27.10 | 38.51 | 45.57 | 54.44 | 66.64 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Mar 2017
- Equity Capital
- 41
- 393
- 110
- Trade Payables
- 162
- 47
- Total Liabilities
- 752
- 267
- Capital Work in Progress
- 0
- 0
- 190
- 0
- Cash & Bank
- 25
- 269
- Total Assets
- 752
- Total Debt
- 110
- Net Working Capital
- 188
- Contingent Liabilities
- 9
- Book Value per Share
- 10.59
- Face Value
- 1.00
- Total Debt
- 110
- Net Working Capital
- 188
- Contingent Liabilities
- 9
- Book Value per Share
- 10.59
- Face Value
- 1.00
Mar 2018
- Equity Capital
- 41
- 430
- 117
- Trade Payables
- 78
- 65
- Total Liabilities
- 731
- 279
- Capital Work in Progress
- 0
- 0
- 218
- 0
- Cash & Bank
- 40
- 193
- Total Assets
- 731
- Total Debt
- 118
- Net Working Capital
- 216
- Contingent Liabilities
- 11
- Book Value per Share
- 11.50
- Face Value
- 1.00
- Total Debt
- 118
- Net Working Capital
- 216
- Contingent Liabilities
- 11
- Book Value per Share
- 11.50
- Face Value
- 1.00
Mar 2019
- Equity Capital
- 41
- 502
- 100
- Trade Payables
- 106
- 54
- Total Liabilities
- 802
- 270
- Capital Work in Progress
- 0
- 0
- 293
- 0
- Cash & Bank
- 34
- 206
- Total Assets
- 802
- Total Debt
- 100
- Net Working Capital
- 299
- Contingent Liabilities
- 30
- Book Value per Share
- 13.25
- Face Value
- 1.00
- Total Debt
- 100
- Net Working Capital
- 299
- Contingent Liabilities
- 30
- Book Value per Share
- 13.25
- Face Value
- 1.00
Mar 2020
- Equity Capital
- 41
- 595
- 19
- Trade Payables
- 110
- 137
- Total Liabilities
- 902
- 303
- Capital Work in Progress
- 0
- 0
- 242
- 0
- Cash & Bank
- 94
- 264
- Total Assets
- 902
- Total Debt
- 19
- Net Working Capital
- 365
- Contingent Liabilities
- 48
- Book Value per Share
- 15.54
- Face Value
- 1.00
- Total Debt
- 19
- Net Working Capital
- 365
- Contingent Liabilities
- 48
- Book Value per Share
- 15.54
- Face Value
- 1.00
Mar 2021
- Equity Capital
- 41
- 846
- 19
- Trade Payables
- 169
- 154
- Total Liabilities
- 1,228
- 309
- Capital Work in Progress
- 6
- 0
- 404
- 0
- Cash & Bank
- 212
- 296
- Total Assets
- 1,228
- Total Debt
- 19
- Net Working Capital
- 604
- Contingent Liabilities
- 20
- Book Value per Share
- 21.66
- Face Value
- 1.00
- Total Debt
- 19
- Net Working Capital
- 604
- Contingent Liabilities
- 20
- Book Value per Share
- 21.66
- Face Value
- 1.00
Mar 2022
- Equity Capital
- 41
- 1,068
- 41
- Trade Payables
- 200
- 310
- Total Liabilities
- 1,660
- 428
- Capital Work in Progress
- 1
- 0
- 424
- 0
- Cash & Bank
- 349
- 457
- Total Assets
- 1,660
- Total Debt
- 41
- Net Working Capital
- 845
- Contingent Liabilities
- 1
- Book Value per Share
- 27.10
- Face Value
- 1.00
- Total Debt
- 41
- Net Working Capital
- 845
- Contingent Liabilities
- 1
- Book Value per Share
- 27.10
- Face Value
- 1.00
Mar 2023
- Equity Capital
- 45
- 1,700
- 42
- Trade Payables
- 231
- 173
- Total Liabilities
- 2,190
- 486
- Capital Work in Progress
- 7
- 1
- 485
- 0
- Cash & Bank
- 715
- 497
- Total Assets
- 2,190
- Total Debt
- 42
- Net Working Capital
- 1,334
- Contingent Liabilities
- 1
- Book Value per Share
- 38.51
- Face Value
- 1.00
- Total Debt
- 42
- Net Working Capital
- 1,334
- Contingent Liabilities
- 1
- Book Value per Share
- 38.51
- Face Value
- 1.00
Mar 2024
- Equity Capital
- 45
- 2,020
- 29
- Trade Payables
- 268
- 319
- Total Liabilities
- 2,681
- 776
- Capital Work in Progress
- 5
- 27
- 618
- 453
- Cash & Bank
- 674
- 128
- Total Assets
- 2,681
- Total Debt
- 29
- Net Working Capital
- 1,473
- Contingent Liabilities
- 0
- Book Value per Share
- 45.57
- Face Value
- 1.00
- Total Debt
- 29
- Net Working Capital
- 1,473
- Contingent Liabilities
- 0
- Book Value per Share
- 45.57
- Face Value
- 1.00
Mar 2025
- Equity Capital
- 45
- 2,422
- 23
- Trade Payables
- 306
- 444
- Total Liabilities
- 3,240
- 982
- Capital Work in Progress
- 9
- 1
- 846
- 540
- Cash & Bank
- 704
- 158
- Total Assets
- 3,240
- Total Debt
- 23
- Net Working Capital
- 1,727
- Contingent Liabilities
- 0
- Book Value per Share
- 54.44
- Face Value
- 1.00
- Total Debt
- 23
- Net Working Capital
- 1,727
- Contingent Liabilities
- 0
- Book Value per Share
- 54.44
- Face Value
- 1.00
Mar 2026
- Equity Capital
- 45
- 2,975
- 30
- Trade Payables
- 337
- 462
- Total Liabilities
- 3,848
- 1,044
- Capital Work in Progress
- 15
- 0
- 972
- 645
- Cash & Bank
- 990
- 183
- Total Assets
- 3,848
- Total Debt
- 30
- Net Working Capital
- 2,196
- Contingent Liabilities
- 0
- Book Value per Share
- 66.64
- Face Value
- 1.00
- Total Debt
- 30
- Net Working Capital
- 2,196
- Contingent Liabilities
- 0
- Book Value per Share
- 66.64
- Face Value
- 1.00
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 | |
| Cash from Investing | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -248 |
| Cash from Financing | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 | 93 | 139 | |
| Free Cash Flow | -13 | 12 | 16 | 174 | 179 | -70 | 129 | -74 | -75 | 260 |
| OCF / Net Profit | 1.24 | 1.40 | 0.34 | 1.93 | 0.75 | 0.53 | 0.89 | 0.73 | 0.54 | 1.09 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 368 | 311 | 428 | 337 | 88 | 169 |
| OCF / Net Profit | 1.24 | 1.40 | 0.34 | 1.93 | 0.75 | 0.53 | 0.89 | 0.73 | 0.54 | 1.09 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 368 | 311 | 428 | 337 | 88 | 169 |
Mar 2017
- 14
- Cash from Investing
- -21
- Cash from Financing
- -3
- -10
- Free Cash Flow
- -13
- OCF / Net Profit
- 1.24
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.24
- Cumulative 5-Year FCF
- 0
Mar 2018
- 50
- Cash from Investing
- -39
- Cash from Financing
- 3
- 15
- Free Cash Flow
- 12
- OCF / Net Profit
- 1.40
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.40
- Cumulative 5-Year FCF
- 0
Mar 2019
- 27
- Cash from Investing
- -13
- Cash from Financing
- -21
- -7
- Free Cash Flow
- 16
- OCF / Net Profit
- 0.34
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.34
- Cumulative 5-Year FCF
- 0
Mar 2020
- 233
- Cash from Investing
- -60
- Cash from Financing
- -114
- 60
- Free Cash Flow
- 174
- OCF / Net Profit
- 1.93
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.93
- Cumulative 5-Year FCF
- 0
Mar 2021
- 179
- Cash from Investing
- -45
- Cash from Financing
- -15
- 118
- Free Cash Flow
- 179
- OCF / Net Profit
- 0.75
- Cumulative 5-Year FCF
- 368
- OCF / Net Profit
- 0.75
- Cumulative 5-Year FCF
- 368
Mar 2022
- 99
- Cash from Investing
- -84
- Cash from Financing
- 80
- 94
- Free Cash Flow
- -70
- OCF / Net Profit
- 0.53
- Cumulative 5-Year FCF
- 311
- OCF / Net Profit
- 0.53
- Cumulative 5-Year FCF
- 311
Mar 2023
- 237
- Cash from Investing
- -259
- Cash from Financing
- 198
- 176
- Free Cash Flow
- 129
- OCF / Net Profit
- 0.89
- Cumulative 5-Year FCF
- 428
- OCF / Net Profit
- 0.89
- Cumulative 5-Year FCF
- 428
Mar 2024
- 230
- Cash from Investing
- -141
- Cash from Financing
- -69
- 21
- Free Cash Flow
- -74
- OCF / Net Profit
- 0.73
- Cumulative 5-Year FCF
- 337
- OCF / Net Profit
- 0.73
- Cumulative 5-Year FCF
- 337
Mar 2025
- 207
- Cash from Investing
- -49
- Cash from Financing
- -65
- 93
- Free Cash Flow
- -75
- OCF / Net Profit
- 0.54
- Cumulative 5-Year FCF
- 88
- OCF / Net Profit
- 0.54
- Cumulative 5-Year FCF
- 88
Mar 2026
- 458
- Cash from Investing
- -248
- Cash from Financing
- -71
- 139
- Free Cash Flow
- 260
- OCF / Net Profit
- 1.09
- Cumulative 5-Year FCF
- 169
- OCF / Net Profit
- 1.09
- Cumulative 5-Year FCF
- 169
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | - | - | - | - | - | - | - | - | - | - |
| EPS (₹) | 0.22 | 0.80 | 1.87 | 2.86 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 9.22 |
| Book Value (₹) | 10.59 | 11.50 | 13.25 | 15.54 | 21.66 | 27.10 | 38.51 | 45.57 | 54.44 | 66.64 |
| Dividend per Share (₹) | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.60 | 0.80 | 0.90 |
| Cash EPS (₹) | 1.01 | 1.53 | 2.52 | 3.60 | 6.71 | 5.66 | 7.00 | 8.59 | 10.28 | 11.45 |
| PROFITABILITY | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 6.75% | 9.52% | 13.68% | 16.98% | 24.88% | 19.42% | 19.55% | 20.03% | 19.39% | 19.78% |
| Net Margin % | 1.48% | 3.92% | 8.04% | 10.65% | 17.14% | 12.06% | 13.01% | 13.75% | 13.93% | 13.83% |
| ROE % | 2.59% | 7.92% | 15.88% | 20.49% | 31.33% | 18.72% | 18.59% | 16.53% | 16.89% | 15.31% |
| ROCE % | 4.00% | 10.60% | 18.51% | 25.57% | 39.76% | 23.82% | 22.89% | 22.40% | 22.50% | 21.10% |
| 1.54% | 4.83% | 10.49% | 14.17% | 22.40% | 12.94% | 13.78% | 12.93% | 12.93% | 11.85% | |
| EFFICIENCY | - | - | - | - | - | - | - | - | - | - |
| Debtor Days | 111 | 85 | 65 | 68 | 68 | 79 | 73 | 69 | 66 | 71 |
| Inventory Days | 85 | 82 | 93 | 86 | 85 | 98 | 81 | 88 | 97 | 109 |
| Payable Days | 112 | 84 | 67 | 70 | 86 | 94 | 85 | 88 | 92 | 92 |
| 84 | 83 | 90 | 84 | 67 | 82 | 69 | 70 | 72 | 89 | |
| FINANCIAL HEALTH | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity (x) | 0.25x | 0.25x | 0.18x | 0.03x | 0.02x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x |
| Interest Coverage (x) | 3.19x | 5.87x | 11.80x | 18.97x | 38.84x | 30.31x | 37.99x | 38.80x | 44.22x | 24.24x |
| 1.63x | 1.92x | 2.28x | 2.59x | 3.02x | 3.22x | 4.91x | 4.78x | 4.62x | 5.17x | |
| GROWTH | - | - | - | - | - | - | - | - | - | - |
| Revenue Growth % | -14.12% | 18.97% | 9.57% | 13.41% | 21.33% | 8.33% | 24.23% | 17.56% | 20.46% | 12.51% |
| Operating Profit Growth % | -64.32% | 67.79% | 57.46% | 40.81% | 79.82% | -13.16% | 32.55% | 27.69% | 17.68% | 14.07% |
| Net Profit Growth % | -86.30% | 215.87% | 124.68% | 50.12% | 97.54% | -21.68% | 42.02% | 18.68% | 21.51% | 9.79% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17.80% | 21.32% | 9.81% | |
| VALUATION | - | - | - | - | - | - | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 21.89x | 26.48x | 17.04x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 3.33x | 4.08x | 2.36x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.40% | 0.36% | 0.57% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 12.23x | 15.68x | 9.02x |
Mar 2017
- EPS (₹)
- 0.22
- Book Value (₹)
- 10.59
- Dividend per Share (₹)
- 0.05
- Cash EPS (₹)
- 1.01
- Operating Margin %
- 6.75%
- Net Margin %
- 1.48%
- ROE %
- 2.59%
- ROCE %
- 4.00%
- 1.54%
- Debtor Days
- 111
- Inventory Days
- 85
- Payable Days
- 112
- 84
- Debt to Equity (x)
- 0.25x
- Interest Coverage (x)
- 3.19x
- 1.63x
- Revenue Growth %
- -14.12%
- Operating Profit Growth %
- -64.32%
- Net Profit Growth %
- -86.30%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2018
- EPS (₹)
- 0.80
- Book Value (₹)
- 11.50
- Dividend per Share (₹)
- 0.05
- Cash EPS (₹)
- 1.53
- Operating Margin %
- 9.52%
- Net Margin %
- 3.92%
- ROE %
- 7.92%
- ROCE %
- 10.60%
- 4.83%
- Debtor Days
- 85
- Inventory Days
- 82
- Payable Days
- 84
- 83
- Debt to Equity (x)
- 0.25x
- Interest Coverage (x)
- 5.87x
- 1.92x
- Revenue Growth %
- 18.97%
- Operating Profit Growth %
- 67.79%
- Net Profit Growth %
- 215.87%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2019
- EPS (₹)
- 1.87
- Book Value (₹)
- 13.25
- Dividend per Share (₹)
- 0.05
- Cash EPS (₹)
- 2.52
- Operating Margin %
- 13.68%
- Net Margin %
- 8.04%
- ROE %
- 15.88%
- ROCE %
- 18.51%
- 10.49%
- Debtor Days
- 65
- Inventory Days
- 93
- Payable Days
- 67
- 90
- Debt to Equity (x)
- 0.18x
- Interest Coverage (x)
- 11.80x
- 2.28x
- Revenue Growth %
- 9.57%
- Operating Profit Growth %
- 57.46%
- Net Profit Growth %
- 124.68%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2020
- EPS (₹)
- 2.86
- Book Value (₹)
- 15.54
- Dividend per Share (₹)
- 0.10
- Cash EPS (₹)
- 3.60
- Operating Margin %
- 16.98%
- Net Margin %
- 10.65%
- ROE %
- 20.49%
- ROCE %
- 25.57%
- 14.17%
- Debtor Days
- 68
- Inventory Days
- 86
- Payable Days
- 70
- 84
- Debt to Equity (x)
- 0.03x
- Interest Coverage (x)
- 18.97x
- 2.59x
- Revenue Growth %
- 13.41%
- Operating Profit Growth %
- 40.81%
- Net Profit Growth %
- 50.12%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2021
- EPS (₹)
- 5.76
- Book Value (₹)
- 21.66
- Dividend per Share (₹)
- 0.25
- Cash EPS (₹)
- 6.71
- Operating Margin %
- 24.88%
- Net Margin %
- 17.14%
- ROE %
- 31.33%
- ROCE %
- 39.76%
- 22.40%
- Debtor Days
- 68
- Inventory Days
- 85
- Payable Days
- 86
- 67
- Debt to Equity (x)
- 0.02x
- Interest Coverage (x)
- 38.84x
- 3.02x
- Revenue Growth %
- 21.33%
- Operating Profit Growth %
- 79.82%
- Net Profit Growth %
- 97.54%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2022
- EPS (₹)
- 4.51
- Book Value (₹)
- 27.10
- Dividend per Share (₹)
- 0.25
- Cash EPS (₹)
- 5.66
- Operating Margin %
- 19.42%
- Net Margin %
- 12.06%
- ROE %
- 18.72%
- ROCE %
- 23.82%
- 12.94%
- Debtor Days
- 79
- Inventory Days
- 98
- Payable Days
- 94
- 82
- Debt to Equity (x)
- 0.04x
- Interest Coverage (x)
- 30.31x
- 3.22x
- Revenue Growth %
- 8.33%
- Operating Profit Growth %
- -13.16%
- Net Profit Growth %
- -21.68%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2023
- EPS (₹)
- 5.88
- Book Value (₹)
- 38.51
- Dividend per Share (₹)
- 0.50
- Cash EPS (₹)
- 7.00
- Operating Margin %
- 19.55%
- Net Margin %
- 13.01%
- ROE %
- 18.59%
- ROCE %
- 22.89%
- 13.78%
- Debtor Days
- 73
- Inventory Days
- 81
- Payable Days
- 85
- 69
- Debt to Equity (x)
- 0.02x
- Interest Coverage (x)
- 37.99x
- 4.91x
- Revenue Growth %
- 24.23%
- Operating Profit Growth %
- 32.55%
- Net Profit Growth %
- 42.02%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2024
- EPS (₹)
- 6.92
- Book Value (₹)
- 45.57
- Dividend per Share (₹)
- 0.60
- Cash EPS (₹)
- 8.59
- Operating Margin %
- 20.03%
- Net Margin %
- 13.75%
- ROE %
- 16.53%
- ROCE %
- 22.40%
- 12.93%
- Debtor Days
- 69
- Inventory Days
- 88
- Payable Days
- 88
- 70
- Debt to Equity (x)
- 0.01x
- Interest Coverage (x)
- 38.80x
- 4.78x
- Revenue Growth %
- 17.56%
- Operating Profit Growth %
- 27.69%
- Net Profit Growth %
- 18.68%
- 17.80%
- P/E (x)
- 21.89x
- P/B (x)
- 3.33x
- Dividend Yield %
- 0.40%
- 12.23x
Mar 2025
- EPS (₹)
- 8.40
- Book Value (₹)
- 54.44
- Dividend per Share (₹)
- 0.80
- Cash EPS (₹)
- 10.28
- Operating Margin %
- 19.39%
- Net Margin %
- 13.93%
- ROE %
- 16.89%
- ROCE %
- 22.50%
- 12.93%
- Debtor Days
- 66
- Inventory Days
- 97
- Payable Days
- 92
- 72
- Debt to Equity (x)
- 0.01x
- Interest Coverage (x)
- 44.22x
- 4.62x
- Revenue Growth %
- 20.46%
- Operating Profit Growth %
- 17.68%
- Net Profit Growth %
- 21.51%
- 21.32%
- P/E (x)
- 26.48x
- P/B (x)
- 4.08x
- Dividend Yield %
- 0.36%
- 15.68x
Mar 2026
- EPS (₹)
- 9.22
- Book Value (₹)
- 66.64
- Dividend per Share (₹)
- 0.90
- Cash EPS (₹)
- 11.45
- Operating Margin %
- 19.78%
- Net Margin %
- 13.83%
- ROE %
- 15.31%
- ROCE %
- 21.10%
- 11.85%
- Debtor Days
- 71
- Inventory Days
- 109
- Payable Days
- 92
- 89
- Debt to Equity (x)
- 0.01x
- Interest Coverage (x)
- 24.24x
- 5.17x
- Revenue Growth %
- 12.51%
- Operating Profit Growth %
- 14.07%
- Net Profit Growth %
- 9.79%
- 9.81%
- P/E (x)
- 17.04x
- P/B (x)
- 2.36x
- Dividend Yield %
- 0.57%
- 9.02x
Documents
Announcements
- Analysts/Institutional Investor Meet/Con. Call Updates
2026-08-20 - Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Financial Results
- Analysts/Institutional Investor Meet/Con. Call Updates
2026-08-13 - Marksans Pharma Limited has informed the Exchange about Link of Recording of Conference call Q1 FY 27 Financial Results
Annual Reports
Credit Ratings
- Credit Rating- Revision
2026-06-09 - Marksans Pharma Limited has informed the Exchange that India Ratings and Research has revised the outlook for the Company s bank loan facilities to Positive from Stable
Concalls
Aug 2026
Jun 2026
May 2026